Meet-the-Professor Session:
97. Hepatitis C: Case-Based Discussion of HCV Treatment in the DAA Era
Friday, October 5, 2018: 7:15 AM-8:15 AM
Room: S 214-216

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • discuss the recommendations for treatment of HCV using direct acting antiviral therapy
  • discuss the approach to treatment of HCV for special populations including patients with HIV-infection
  • discuss testing required prior to HCV therapy

Target Audience: Academicians, Clinicians, Fellows, HIV clinicians, HIV specialists, Infectious diseases physicians, Medical students and residents, Members-in-training, Nurses, Pharmacists, Public health practitioners

Tracks: Pediatric ID, HIV-STD-TB, Global ID, Adult ID


Moderator:  Susanna Naggie, MD, MHS, Duke University Medical Center, Duke Clinical Research Institute

CME Credits: Maximum of 1.00 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1 knowledge-based contact hours of pharmacy CE

ACPE Number: 0221-9999-18-216-L01-P

Disclosures:

S. Naggie, Gilead: Investigator , Research grant . AbbVie: Investigator , Research support . Janssen: Investigator , Research support . Merck: Investigator , Research support . Tacere: Investigator , Research support .

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.